ALK and non-small cell lung carcinoma: In our study, TP53 mutations were observed in 43.74% (423/967) of all EGFR-mutated patients and 30.72% (90/293) of all ALK-mutated NSCLC cases, which were in accordance with previous reports [49, 50].